MicroRNAs as novel immunotherapeutics

OncoImmunology

Volumn 2, Issue 8, 2013, Pages

  Heimberger, Amy B ^a   Gilbert, Mark ^a   Rao, Ganesh ^a   Wei, Jun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer stem cells; Glioblastoma multiforme; Immunosuppression; MicroRNAs; Regulatory T cells; Signal transducer and activator of transcription 3

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 6; MICRORNA 124; MICRORNA 142 3P; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRADING; CANCER IMMUNOTHERAPY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSURVEILLANCE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84885744161     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25124     Document Type: Article

References (10)

1. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11:1314-21; PMID:16288283; http://dx.doi.org/10.1038/nm1325
2. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 2010; 9:67-78; PMID:20053772; http:// dx.doi.org/10.1158/1535-7163.MCT-09-0734
3. Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 2010; 12:1113-25; PMID:20667896; http://dx.doi.org/10.1093/neuonc/ noq082
4. Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, et al. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res 2013; In press; PMID:23636127; http:// dx.doi.org/10.1158/0008-5472.CAN-12-4318
5. Xu S, Wei J, Wang F, Kong LY, Ling XY, Doucette TA, et al. miR-142-3p inhibits the M2 macrophage and exerts therapeutic efficacy against murine glioblastoma. In Review.
6. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006; 9:341-9; PMID:16697955; http://dx.doi. org/10.1016/j.ccr.2006.03.029
7. Mellinghoff IKWM, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012-24; PMID:16282176; http://dx.doi.org/10.1056/ NEJMoa051918
8. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007; 67:9630-6; PMID:17942891; http://dx.doi.org/10.1158/0008-5472.CAN-07-1243
9. Ponomarev ED, Veremeyko T, Barteneva N, Krichevsky AM, Weiner HL. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-a-PU.1 pathway. Nat Med 2011; 17:64-70; PMID:21131957; http://dx.doi. org/10.1038/nm.2266
10. Doucette TA, Rao G, Rao A, Shen L, Aldape K, Wei J, et al. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunology Research